Financial toxicity in cancer care—Edging toward solutions

@article{Goldstein2017FinancialTI,
  title={Financial toxicity in cancer care—Edging toward solutions},
  author={Daniel A. Goldstein},
  journal={Cancer},
  year={2017},
  volume={123}
}
Financial toxicity is now a well established and generally accepted toxicity related to cancer care. In this issue of Cancer, Zheng et al have added further information to enrich our understanding of the financial challenges faced by cancer survivors. In recent years, several reports have demonstrated the significant financial issues faced by some patients with cancer. A study in the state of Washington demonstrated that individuals with cancer are 2.7 times more likely to declare bankruptcy… 

Reply to Improving the survival of patients with American Joint Committee on Cancer stage III and IV melanoma

TLDR
The modestly improving survival reported from the SEER database may be due to the relatively slow adoption of targeted therapies in major cancer centers, such as the Moffitt Cancer Center.

Improving the survival of patients with American Joint Committee on Cancer stage III and IV melanoma

TLDR
The modestly improving survival reported from the SEER database may be due to the relatively slow adoption of targeted therapies in major cancer centers, such as the Moffitt Cancer Center.

Hospital Price Transparency Rule Exposes Muddied Costs for Head and Neck Radiotherapy in One State

TLDR
There is a wide range of treatment costs for HNC patients receiving definitive radiotherapy in Ohio, and no variables fully explain this variance, suggesting further policies are needed to improve the quality, quantity, and accessibility of health care data.

Coping mechanisms for financial toxicity: a qualitative study of cancer patients’ experiences in Germany

TLDR
This qualitative study provides a comprehensive understanding of the complexity of the coping mechanisms used by patients to address either higher costs or changed needs and priorities following a cancer diagnosis.

Association of high cost sharing and targeted therapy initiation among elderly Medicare patients with metastatic renal cell carcinoma

TLDR
High cost sharing was associated with reduced and/or delayed access to targeted therapies under Medicare Part D, suggesting that financial barriers play a role in treatment decisions.

Association of Patient Out-of-Pocket Costs With Prescription Abandonment and Delay in Fills of Novel Oral Anticancer Agents.

TLDR
Higher OOP costs were associated with higher rates of oral prescription abandonment and delayed initiation across cancers, and fiscally sustainable strategies are needed to improve patient access to cancer medications.

A qualitative analysis and development of a conceptual model assessing financial toxicity in cancer patients accessing the universal healthcare system

TLDR
This qualitative study represents the first part of a study conducted to develop a new PROM to assess FT in Italy, by using a bottom-up approach that makes the most of patients’ experiences and the health system analysis.

Salvage Radiopeptide Therapy of Advanced Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen: Efficacy and Safety in Routine Practice.

TLDR
177Lu-PSMA I&T radioimmunotherapy of progressive mCRPC is safe and effective with three cycles being the potential optimal number for determining long-term disease response.

Patterns of oral and dental care education and utilization in head and neck cancer patients

TLDR
There is a general lack of consistency with how, when, and from whom oral cancer patients receive their oral health education, and this contributes to insufficient education resulting in high levels of patient dissatisfaction with their oral care.

Health-Related Quality of Life: The Impact on Morbidity and Mortality.

References

SHOWING 1-10 OF 10 REFERENCES

The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience.

TLDR
Insured patients undergoing cancer treatment and seeking copayment assistance experience considerable subjective financial burden, and they may alter their care to defray out-of-pocket expenses.

Financial Insolvency as a Risk Factor for Early Mortality Among Patients With Cancer.

  • S. RamseyA. Bansal P. Newcomb
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2016
TLDR
Severe financial distress requiring bankruptcy protection after cancer diagnosis appears to be a risk factor for mortality, according to Cox proportional hazards models.

Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis.

TLDR
Findings suggest that employers and governments may have a policy role to play in creating programs and incentives that could help people cover expenses in the first year following a cancer diagnosis and that Medicare and Social Security may mitigate bankruptcy risk for the older group.

Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States.

  • Qiushi ChenN. Jain J. Chhatwal
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2017
TLDR
The increased benefit and cost of oral targeted therapies is projected to enhance CLL survivorship but can impose a substantial financial burden on both patients and payers.

Out-of-Pocket Spending and Financial Burden Among Medicare Beneficiaries With Cancer

TLDR
Medicare reform proposals that restructure the benefit design for hospital-based services and incorporate an OOP maximum may help alleviate financial burden, as can interventions that reduce hospitalization in this population.

Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia.

TLDR
A critical need to reduce patient costs for TKI adherence and discontinuation is suggested, as patients with higher copayments are more likely to discontinue or be nonadherent to TKIs.

Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer.

  • A. NeugutM. Subar D. Hershman
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2011
TLDR
It was found that higher prescription co-payments were associated with both nonpersistence and nonadherence to AIs, and this relationship was stronger in older women.

Estimating regimen‐specific costs of chemotherapy for breast cancer: Observational cohort study

TLDR
The objective of the current study was to generate cost estimates for breast cancer regimens from payers’ and patients’ perspectives in a large, insured US population.

Considering Efficacy and Cost, Where Does Ramucirumab Fit in the Management of Metastatic Colorectal Cancer?

Health care institutions, physicians, and patients can—and should—be more involved in evaluating the role of new therapies such as ramucirumab in metastatic colorectal cancer based on their value.

Do cancer survivors change their prescription drug use for financial reasons? Findings from a nationally representative sample in the United States

There is limited evidence from nationally representative samples about changes in prescription drug use for financial reasons among cancer survivors in the United States.